A short regimen for rifapin-resistant tuberculosis was noninferior to 20-month regimen.
Chronic pulmonary aspergillosis complicates treated pulmonary tuberculosis frequently.
In a subgroup of patients with multidrug-resistant tuberculosis, vitamin D supplementation accelerated sputum culture conversion.
Delamanid was safe and tolerable during a 6-month treatment period in patients with multidrug-resistant tuberculosis.
Risk for developing active tuberculosis has not been previously assessed in patients undergoing hematopoietic cell transplantation.
Introducing pyrazinamide molecular susceptibility testing in the treatment of multidrug-resistant tuberculosis improved outcomes without the use of new drugs and shortened the World Health Organization 20+ month regimen to 12 months.
A freeze-dried, temperature-stable, experimental tuberculosis vaccine candidate has entered a phase 1 human clinical trial.
A new vaccine candidate may stave off active TB in M tuberculosis-infected adults.